1
|
Wachter S, Angevin T, Bubna N, Tan A, Cichy A, Brown D, Wolfe LS, Sappington R, Lilla E, Berry L, Grismer D, Orth C, Blanusa M, Mostafa S, Kaufmann H, Felderer K. Application of platform process development approaches to the manufacturing of Mabcalin™ bispecifics. J Biotechnol 2023; 377:13-22. [PMID: 37820750 DOI: 10.1016/j.jbiotec.2023.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 09/28/2023] [Accepted: 10/06/2023] [Indexed: 10/13/2023]
Abstract
Bispecific biotherapeutics offer potent and highly specific treatment options in oncology and immuno-oncology. However, many bispecific formats are prone to high levels of aggregation and instability, leading to prolonged development timelines, inefficient manufacturing, and high costs. The novel class of Mabcalin™ molecules consist of Anticalin® proteins fused to an IgG and are currently being evaluated in pre-clinical and clinical studies. Here, we describe a robust high-yield manufacturing platform for these therapeutic fusion proteins providing data up to commercially relevant scales. A platform upstream process was established for one of the Mabcalin bispecifics and then applied to other clinically relevant drug candidates with different IgG target specificities. Process performance was compared in 3 L bioreactors and production was scaled-up to up to 1000 L for confirmation. The Mabcalin proteins' structural and biophysical similarities enabled a downstream platform approach consisting of initial protein A capture, viral inactivation, mixed-mode anion exchange polishing, second polishing by cation exchange or hydrophobic interaction chromatography, viral filtration, buffer exchange and concentration by ultrafiltration/diafiltration. All three processes met their target specifications and achieved comparable clearance of impurities and product yields across scales. The described platform approach provides a fast and economic path to process confirmation and is well comparable to classical monoclonal antibody approaches in terms of costs and time to clinic.
Collapse
Affiliation(s)
- Stefanie Wachter
- Pieris Pharmaceuticals GmbH, Zeppelinstr. 3, Hallbergmoos 85399 Germany.
| | - Thibaut Angevin
- Pieris Pharmaceuticals GmbH, Zeppelinstr. 3, Hallbergmoos 85399 Germany
| | - Niket Bubna
- KBI Biopharma, 4117 Emperor Blvd, Suite 200, Durham, NC 27703, USA
| | - Adelene Tan
- Pieris Pharmaceuticals GmbH, Zeppelinstr. 3, Hallbergmoos 85399 Germany
| | - Adam Cichy
- Pieris Pharmaceuticals GmbH, Zeppelinstr. 3, Hallbergmoos 85399 Germany
| | - David Brown
- KBI Biopharma, 4117 Emperor Blvd, Suite 200, Durham, NC 27703, USA
| | - Leslie S Wolfe
- KBI Biopharma, 4117 Emperor Blvd, Suite 200, Durham, NC 27703, USA
| | - Ryan Sappington
- KBI Biopharma, 4117 Emperor Blvd, Suite 200, Durham, NC 27703, USA
| | - Edward Lilla
- KBI Biopharma, 4117 Emperor Blvd, Suite 200, Durham, NC 27703, USA
| | - Luke Berry
- KBI Biopharma, 4117 Emperor Blvd, Suite 200, Durham, NC 27703, USA
| | - Dane Grismer
- KBI Biopharma, 4117 Emperor Blvd, Suite 200, Durham, NC 27703, USA
| | - Christian Orth
- Pieris Pharmaceuticals GmbH, Zeppelinstr. 3, Hallbergmoos 85399 Germany
| | - Milan Blanusa
- Pieris Pharmaceuticals GmbH, Zeppelinstr. 3, Hallbergmoos 85399 Germany
| | - Sigma Mostafa
- KBI Biopharma, 4117 Emperor Blvd, Suite 200, Durham, NC 27703, USA
| | - Hitto Kaufmann
- Pieris Pharmaceuticals GmbH, Zeppelinstr. 3, Hallbergmoos 85399 Germany
| | - Karin Felderer
- Pieris Pharmaceuticals GmbH, Zeppelinstr. 3, Hallbergmoos 85399 Germany
| |
Collapse
|
2
|
Neuber T, Frese K, Jaehrling J, Jäger S, Daubert D, Felderer K, Linnemann M, Höhne A, Kaden S, Kölln J, Tiller T, Brocks B, Ostendorp R, Pabst S. Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs 2014; 6:928-42. [PMID: 24802048 DOI: 10.4161/mabs.28744] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The neonatal Fc receptor (FcRn) protects immunoglobulin G (IgG) from degradation and increases the serum half-life of IgG, thereby contributing to a higher concentration of IgG in the serum. Because altered FcRn binding may result in a reduced or prolonged half-life of IgG molecules, it is advisable to characterize Fc receptor binding of therapeutic antibody lead candidates prior to the start of pre-clinical and clinical studies. In this study, we characterized the interactions between FcRn of different species (human, cynomolgus monkey, mouse and rat) and nine IgG molecules from different species and isotypes with common variable heavy (VH) and variable light chain (VL) domains. Binding was analyzed at acidic and neutral pH using surface plasmon resonance (SPR) and biolayer interferometry (BLI). Furthermore, we transferred the well-accepted, but low throughput SPR-based method for FcRn binding characterization to the BLI-based Octet platform to enable a higher sample throughput allowing the characterization of FcRn binding already during early drug discovery phase. We showed that the BLI-based approach is fit-for-purpose and capable of discriminating between IgG molecules with significant differences in FcRn binding affinities. Using this high-throughput approach we investigated FcRn binding of 36 IgG molecules that represented all VH/VL region combinations available in the fully human, recombinant antibody library Ylanthia®. Our results clearly showed normal FcRn binding profiles for all samples. Hence, the variations among the framework parts, complementarity-determining region (CDR) 1 and CDR2 of the fragment antigen binding (Fab) domain did not significantly change FcRn binding.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Anne Höhne
- MorphoSys AG; Martinsried/Planegg, Germany
| | | | | | | | | | | | | |
Collapse
|
3
|
Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, Heßling M, Daubert D, Felderer K, Kaden S, Kölln J, Enzelberger M, Urlinger S. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs 2013; 5:445-70. [PMID: 23571156 DOI: 10.4161/mabs.24218] [Citation(s) in RCA: 147] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
This report describes the design, generation and testing of Ylanthia, a fully synthetic human Fab antibody library with 1.3E+11 clones. Ylanthia comprises 36 fixed immunoglobulin (Ig) variable heavy (VH)/variable light (VL) chain pairs, which cover a broad range of canonical complementarity-determining region (CDR) structures. The variable Ig heavy and Ig light (VH/VL) chain pairs were selected for biophysical characteristics favorable to manufacturing and development. The selection process included multiple parameters, e.g., assessment of protein expression yield, thermal stability and aggregation propensity in fragment antigen binding (Fab) and IgG1 formats, and relative Fab display rate on phage. The framework regions are fixed and the diversified CDRs were designed based on a systematic analysis of a large set of rearranged human antibody sequences. Care was taken to minimize the occurrence of potential posttranslational modification sites within the CDRs. Phage selection was performed against various antigens and unique antibodies with excellent biophysical properties were isolated. Our results confirm that quality can be built into an antibody library by prudent selection of unmodified, fully human VH/VL pairs as scaffolds.
Collapse
|
4
|
Felderer K, Groves M, Diez J, Pohl E, Witt S. Crystallization and preliminary X-ray analysis of the Thermoplasma acidophilum 20S proteasome in complex with protein substrates. Acta Crystallogr Sect F Struct Biol Cryst Commun 2008; 64:899-902. [PMID: 18931431 DOI: 10.1107/s1744309108026791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2008] [Accepted: 08/20/2008] [Indexed: 11/10/2022]
Abstract
The 20S proteasome is a 700 kDa barrel-shaped proteolytic complex that is traversed by an internal channel which widens into three cavities: two antechambers and one central chamber. Entrance to the complex is restricted by the narrow opening of the channel, which only allows unfolded substrates to reach the active sites located within the central cavity. The X-ray structures of 20S proteasomes from different organisms with and without inhibitors bound have led to a detailed knowledge of their structure and proteolytic function. Nevertheless, the mechanisms that underlie substrate translocation into the 20S proteasome and the role of the antechambers remain elusive. To investigate putative changes within the proteasome that occur during substrate translocation, ;host-guest' complexes between the Thermoplasma acidophilum 20S proteasomes and either cytochrome c (cyt c) or green fluorescent protein (GFP) were produced and crystallized. Orthorhombic crystals belonging to space group P2(1)2(1)2(1), with unit-cell parameters a = 116, b = 207, c = 310 A (cyt c) and a = 116, b = 206, c = 310 A (GFP), were formed and X-ray diffraction data were collected to 3.4 A (cyt c) and 3.8 A (GFP) resolution.
Collapse
Affiliation(s)
- Karin Felderer
- Department of Molecular Structural Biology, Max-Planck Institute of Biochemistry, Am Klopferspitz 18, D-82152 Martinsried, Germany
| | | | | | | | | |
Collapse
|
5
|
Witt S, Kwon YD, Sharon M, Felderer K, Beuttler M, Robinson CV, Baumeister W, Jap BK. Proteasome Assembly Triggers a Switch Required for Active-Site Maturation. Structure 2006; 14:1179-88. [PMID: 16843899 DOI: 10.1016/j.str.2006.05.019] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2005] [Revised: 04/20/2006] [Accepted: 05/02/2006] [Indexed: 11/15/2022]
Abstract
The processing of propeptides and the maturation of 20S proteasomes require the association of beta rings from two half proteasomes. We propose an assembly-dependent activation model in which interactions between helix (H3 and H4) residues of the opposing half proteasomes are prerequisite for appropriate positioning of the S2-S3 loop; such positioning enables correct coordination of the active-site residue needed for propeptide cleavage. Mutations of H3 or H4 residues that participate in the association of two half proteasomes inhibit activation and prevent, in nearly all cases, the formation of full proteasomes. In contrast, mutations affecting interactions with residues of the S2-S3 loop allow the assembly of full, but activity impacted, proteasomes. The crystal structure of the inactive H3 mutant, Phe145Ala, shows that the S2-S3 loop is displaced from the position observed in wild-type proteasomes. These data support the proposed assembly-dependent activation model in which the S2-S3 loop acts as an activation switch.
Collapse
Affiliation(s)
- Susanne Witt
- Department of Molecular Structural Biology, Max-Planck-Institute of Biochemistry, Martinsried 82152, Germany
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Sharon M, Witt S, Felderer K, Rockel B, Baumeister W, Robinson CV. 20S Proteasomes Have the Potential to Keep Substrates in Store for Continual Degradation. J Biol Chem 2006; 281:9569-75. [PMID: 16446364 DOI: 10.1074/jbc.m511951200] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The 20S core of the proteasome, which together with the regulatory particle plays a major role in the degradation of proteins in eukaryotic cells, is traversed by an internal system of cavities, namely two antechambers and one central proteolytic chamber. Little is known about the mechanisms underlying substrate binding and translocation of polypeptide chains into the interior of 20S proteasomes. Specifically, the role of the antechambers is not fully understood, and the number of substrate molecules sequestered within the internal cavities at any one time is unknown. Here we have shown that by applying both electron microscopy and tandem mass spectrometry (MS) approaches to this multisubunit complex we obtain precise information regarding the stoichiometry and location of substrates within the three chambers. The dissociation pattern in tandem MS allows us to conclude that a maximum of three green fluorescent protein and four cytochrome c substrate molecules are bound within the cavities. Our results also show that >95% of the population of proteasome molecules contain the maximum number of partially folded substrates. Moreover, we deduce that one green fluorescent protein or two cytochrome c molecules must reside within the central proteolytic chamber while the remaining substrate molecules occupy, singly, both antechambers. The results imply therefore an additional role for 20S proteasomes in the storage of substrates prior to their degradation, specifically in cases where translocation rates are slower than proteolysis. More generally, the ability to locate relatively small protein ligands sequestered within the 28-subunit core particle highlights the tremendous potential of tandem MS for deciphering substrate binding within large macromolecular assemblies.
Collapse
Affiliation(s)
- Michal Sharon
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | | | | | | | | | | |
Collapse
|
7
|
Frey HG, Witt S, Felderer K, Guckenberger R. High-resolution imaging of single fluorescent molecules with the optical near-field of a metal tip. Phys Rev Lett 2004; 93:200801. [PMID: 15600907 DOI: 10.1103/physrevlett.93.200801] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/15/2004] [Indexed: 05/23/2023]
Abstract
We show that a concentration of light at a metal tip allows near-field optical imaging of single fluorescent dye molecules at very high resolution, despite strong quenching effects. Details as small as 10 nm were observed in the fluorescence patterns of single Cy-3 dyes bound to the termini of DNA. Data evaluation by model fitting determines the positions of the dyes to an accuracy even better than 1 nm and also yields their 3D orientation. The metal tip simultaneously provides high-resolution topographic imaging complementing the optical signal for a detailed surface examination.
Collapse
Affiliation(s)
- Heinrich G Frey
- Max-Planck-Institut für Biochemie, Abteilung Molekulare Strukturbiologie, Am Klopferspitz 18, 82152 Martinsried, Germany
| | | | | | | |
Collapse
|